Abstract
Severe fever with thrombocytopenia syndrome (SFTS), a newly emerging tick-borne viral disease, has been detected in Asia since 2009, and person-to-person transmission is possible. SFTS is characterized by atypical signs, including mild to severe febrile illness similar to that associated with hemorrhagic fever, with 16.2 to 30% mortality. We found that the titers of neutralizing antibodies, play an important role in protective immunity, to SFTS virus (SFTSV) in survivors and healthy residents who lived in endemic areas and who were positive for SFTSV IgG, were higher than those in non-survivor patients. Moreover, the titers were maintained in surviving patients and healthy residents but not in non-surviving patients in South Korea.
Highlights
We briefly investigated the levels of neutralizing antibodies to SFTS virus (SFTSV) in serum among surviving patients, nonsurviving patients, and healthy residents living in endemic areas and who were positive for SFTSV IgG antibody in South Korea from 2013 to 2019 (Yoo et al, 2019)
To investigate the levels of neutralizing antibodies to SFTSV, we collected 19 serum samples from 11 patients, which were laboratory confirmed at Jeju National University from May 2013 to October 2019, Jeju, South Korea, and 7 serum samples from 5 healthy residents living in endemic areas who were positive for SFTSV IgG from November 2015 to April 2017 (Yoo et al, 2019) (Table 1)
A previous study showed that Severe fever with thrombocytopenia syndrome (SFTS) patients produce neutralizing antibodies to SFTSV and can last for four years with a decrease in titers and suggested that neutralizing monoclonal antibody activity blocks the interactions between glycoprotein Gn and cellular receptors (Huang et al, 2016)
Summary
Severe fever with thrombocytopenia syndrome (SFTS), a new tick-borne viral disease with a high mortality rate, was first reported in China in 2009, South Korea in 2010 Japan in 2013, Vietnam in 2017, Myanmar in 2018, and Taiwan in 2019 (Yu et al, 2011; Takahashi et al, 2014; Kim et al, 2018; Tran et al, 2019; Peng et al, 2020; Win et al, 2020). SFTS is characterized by acute high fever, thrombocytopenia, leukopenia, elevated serum hepatic enzyme levels, gastrointestinal symptoms, and multiorgan failure and has a 16.2 to 30% mortality rate (Yu et al, 2011; Takahashi et al, 2014; Peng et al, 2020). We found that the titers of neutralizing antibodies to SFTSV maintained in surviving patients and healthy residents were higher than those detected in non-surviving patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
